當?shù)貢r間1月23日-25日，2025年美國臨床腫瘤學會胃腸道腫瘤研討會（ASCO GI）將在舊金山舉行，旨在傳遞國際消化腫瘤領域的最新研究進展。正大天晴1類創(chuàng)新藥安羅替尼、貝莫蘇拜單抗和派安普利單抗共有9項研究入選，涉及食管癌、肝細胞癌、胃/胃食管結(jié)合部腺癌、結(jié)直腸癌領域。

食管癌

ALTER-E005：安羅替尼聯(lián)合貝莫蘇拜單抗術后輔助治療食管鱗癌的Ⅱ期臨床研究

Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase Ⅱ clinical trial (ALTER-E005)

安羅替尼聯(lián)合派安普利單抗和白蛋白結(jié)合型紫杉醇一線治療晚期食管鱗癌：一項單臂、開放、Ⅱ期臨床研究

Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Ⅱ clinical trial

ALTER-E009初步結(jié)果：安羅替尼聯(lián)合放療治療局晚期或晚期食管鱗癌的療效及安全性，一項多中心、多隊列、回顧性臨床研究

Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exploratory study

安羅替尼聯(lián)合卡度尼利單抗新輔助治療晚期食管鱗癌的單臂、Ⅱ期臨床研究

Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial

肝細胞癌

ALTER-H006結(jié)果更新：貝莫蘇拜單抗聯(lián)合安羅替尼輔助治療根治性切除術后伴高復發(fā)風險的肝細胞癌的Ⅱ期臨床研究

Updated results of ALTER-H006: A phase Ⅱ study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection

ALTER-H004研究結(jié)果更新：安羅替尼聯(lián)合TACE術后輔助治療高復發(fā)風險肝細胞癌，一項單臂、多中心、Ⅱ期臨床研究

Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase Ⅱ clinical

胃/胃食管結(jié)合部腺癌

貝莫蘇拜單抗聯(lián)合安羅替尼和SOX方案一線治療PD-L1低表達晚期胃/胃食管結(jié)合部腺癌：一項單臂、多中心、Ⅱ期臨床研究初步結(jié)果

Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase Ⅱ clinical trial

結(jié)直腸癌

安羅替尼聯(lián)合伊立替康聯(lián)合或不聯(lián)合派安普利單抗二線治療轉(zhuǎn)移性結(jié)直腸癌：ZL-IRIAN研究生存結(jié)果更新

Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer

安羅替尼后線治療晚期結(jié)直腸癌的療效及安全性

Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer

聲明：

1. 本新聞稿旨在促進醫(yī)藥信息的溝通和交流，僅供醫(yī)療衛(wèi)生專業(yè)人士參閱，非廣告用途。

2. 本公司不對任何藥品和/或適應癥作推薦。

3. 本新聞稿中涉及的信息僅供參考，不能以任何方式取代專業(yè)的醫(yī)療指導，也不應被視為診療建議。若您想了解具體疾病診療信息，請遵從醫(yī)生或其他醫(yī)療衛(wèi)生專業(yè)人士的意見或指導。